Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrative single-cell analysis reveals malignant archetypes and proliferative hierarchies in multiple myeloma [Part 3 of 4: Illumina NovaSeq 6000; MARS_v2]

ABSTRACT: Multiple myeloma (MM) is a plasma cell malignancy characterized by substantial genomic and biological heterogeneity, limiting disease classification and development of more targeted therapies. Here, we present a population-level single-cell atlas of MM and detailed clinical annotations from 342 patients representing MM disease and treatment continuum. Our analysis identifies five distinct malignant transcriptional archetypes (MM1–MM5), and a proliferative module variably expressed across archetypes. This proliferation signature emerges as a context-dependent program with independent prognostic value across archetypes. Combined archetype classification with proliferation scoring defines therapeutic resistance, genomic instability, and clinical outcomes. External validation using the CoMMpass cohort confirms the biological robustness and prognostic relevance of this stratification across platforms. Leveraging the resolution of our single-cell atlas, we applied a computational pipeline for therapeutic target discovery based on malignancy, cell-type specificity and tissue restriction. This approach highlights FCRL2 as a promising MM-specific therapeutic target, with selective expression in malignant plasma and B cells at both transcriptomic and protein levels. This integrative analysis provides a clinically actionable blueprint for patient-specific stratification and precision medicine in plasma cell malignancies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE305969 | GEO | 2026/07/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Integrative single-cell analysis reveals malignant archetypes and proliferative hierarchies in multiple myeloma [Part 1 of 4: Illumina NovaSeq 6000; MARS]

Project description:Multiple myeloma (MM) is a plasma cell malignancy characterized by substantial genomic and biological heterogeneity, limiting disease classification and development of more targeted therapies. Here, we present a population-level single-cell atlas of MM and detailed clinical annotations from 342 patients representing MM disease and treatment continuum. Our analysis identifies five distinct malignant transcriptional archetypes (MM1–MM5), and a proliferative module variably expressed across archetypes. This proliferation signature emerges as a context-dependent program with independent prognostic value across archetypes. Combined archetype classification with proliferation scoring defines therapeutic resistance, genomic instability, and clinical outcomes. External validation using the CoMMpass cohort confirms the biological robustness and prognostic relevance of this stratification across platforms. Leveraging the resolution of our single-cell atlas, we applied a computational pipeline for therapeutic target discovery based on malignancy, cell-type specificity and tissue restriction. This approach highlights FCRL2 as a promising MM-specific therapeutic target, with selective expression in malignant plasma and B cells at both transcriptomic and protein levels. This integrative analysis provides a clinically actionable blueprint for patient-specific stratification and precision medicine in plasma cell malignancies.

2026-07-21 | GSE305967 | GEO

Integrative single-cell analysis reveals malignant archetypes and proliferative hierarchies in multiple myeloma [Part 4 of 4: Illumina NovaSeq X; MARS_v2]

2026-07-29 | GSE305970 | GEO

Integrative single-cell analysis reveals malignant archetypes and proliferative hierarchies in multiple myeloma [Part 2 of 4: Illumina NextSeq 500; MARS]

2026-07-21 | GSE305968 | GEO

DKC1: a robust prognostic factor and potential therapeutic target in Multiple Myeloma

Project description:Multiple Myeloma (MM) is an incurable plasma cell malignancy. Dyskerin pseudouridine synthase 1 (DKC1), a nucleolar protein, is essential for RNA modification and cellular homeostasis, yet its role in MM remains unclear. Here, we report that elevated DKC1 expression independently predicted poor outcomes in MM and further refined prognostic stratification beyond the ISS system. Functional assays showed that DKC1 promoted MM cell proliferation, survival, and colony formation, whereas DKC1 knockdown or pharmacological inhibition of DKC1 by pyrazofurin inhibited proliferation and colonies, induced apoptosis, and suppressed tumor growth in xenografts. Mechanistically, DKC1 promotes tumor progression by stabilizing ATF5 mRNA through pseudouridylation, a direct post-transcriptional mechanism evidenced by site-specific pseudouridine mapping. Together, these findings highlight DKC1 as both a critical prognostic biomarker and a promising therapeutic target.

2026-04-15 | GSE308784 | GEO

Impact of Gene Expression Profiling Based Risk Stratification in Patients with Myeloma Receiving Initial Therapy with Lenalidomide and Dexamethasone

Project description:Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma (MM); however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of two GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. The E4A03 clinical trial randomized patients with previously untreated MM to lenalidomide and either standard-dose dexamethasone. Baseline bone marrow samples were obtained from consenting patients. The marrow aspirates were subjected to a fully automated ROBOSEP cell separation system that utilizes immunomagnetic technology to positively select for CD 138+ cells. The purity of the sorting was confirmed by 3-color immunofluorescent slide based assessment on the sorted cells. The plasma cell gene expression proﬁles were analyzed using U133 Plus 2.0 array. All samples were run individually with no pooling. The GEP-70 signature was determined as previously described, using log2 transformed raw MAS 5.0 signals. The GEP15 classification was performed as previously described, with the patients in highest quartile for the risk score being considered as high risk.

2011-08-25 | E-GEOD-31504 | biostudies-arrayexpress

Refining Colorectal Cancer Classification and Clinical Stratification Through a Single-Cell Atlas

Project description:Refining Colorectal Cancer Classification and Clinical Stratification Through a Single-Cell Atlas

| PRJNA827831 | ENA

Clonal evolution in multiple myeloma after treatment pressure: heterogenous genomic aberrations and transcriptomic convergence

Project description:Multiple myeloma (MM) is still an incurable plasma cell malignancy that generally responds well to treatment intitially, but eventually becomes refractory. In the present study, genomic and transcriptomic changes were investigated in paired early and late tumor samples of MM patients .

2022-05-01 | GSE179929 | GEO

Identification of immune reconstitution and hematopoiesis restoration in bone marrow of multiple myeloma patients with high-dose melphalan following auto-HSCT by scRNA-seq

Project description:Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal expansion of plasma cells in the bone marrow (BM). The high-dose chemotherapy following autologous hematopoietic stem cell transplantation (auto-HSCT) is a mainstay therapy for MM. However, effect of therapy on reconstitution of both immune and hematopoietic stem and progenitor cell (HSPCs) in BM of MM patients is pooly understood. In this study, we investigated the significance of that using single-cell RNA sequencing (scRNA-seq). The scRNA-seq data of bone marrow mononuclear cells (BMMCs) from three MM patients with high-dose melphalan following auto-HSCT were integrated these data with scRNA-seq profiles from three newly diagnosed MM patients and three healthy donors. Our data showed that the malignant plasma cells in BM were strongly reduced to 0.09% in the MM group with therapy relative to 22.03% in control MM group. Notably, the proportions of pre-B cells, T cells, natural killer (NK) cells, and HSPCs were significantly elevated to 0.97%, 61.01%, 10.81% and 2.32% in BM of MM groupwith therapy relative to 0.10%, 27.34%, 7.17% and 0.46% in control MM group, indicating a robust reconstitution of both immune and HSPCs. The transcriptional landscape of HSPCs demonstrated functional restoration, with the enrichment of pathways involved in immune activation and multilineage differentiation. Pseudotime analysis revealed the distinct plasma cell trajectories and a notable downregulation of the unfolded protein response (UPR) pathway following by the treatment. Our findings provide a new insight into the comprehensive understanding of single-cell atlas in BM of MM by the therapy.

2026-03-18 | GSE304661 | GEO

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target [Seq]

Project description:Multiple myeloma (MM) is a hematopoietic malignancy characterised by the accumulation of neoplastic post-germinal centre, isotype-switched, long-lived plasma cell within the bone marrow. In genetic and clinical terms MM is highly heterogeneous and remains fatal. Here we present the first epigenomic map of MM derived from freshly isolated bone marrow plasma cells from four patients. Using ChIP- and RNA-sequencing we define a set of silent H3K27me3 targets, active genes bearing H3K4me3, and bivalent genes.

2015-12-31 | GSE53215 | GEO

2015-12-31 | E-GEOD-53215 | biostudies-arrayexpress